News articles about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nymox Pharmaceutical Corporation earned a news impact score of 0.08 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.0712254965384 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Separately, ValuEngine lowered shares of Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a report on Thursday, August 24th.

Nymox Pharmaceutical Corporation (NYMX) opened at 3.73 on Friday. Nymox Pharmaceutical Corporation has a one year low of $2.67 and a one year high of $5.10. The stock’s 50 day moving average is $3.70 and its 200-day moving average is $3.84. The firm’s market cap is $195.33 million.

In other Nymox Pharmaceutical Corporation news, Director James George Robinson acquired 15,000 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was bought at an average price of $3.77 per share, with a total value of $56,550.00. Following the purchase, the director now owns 3,008,150 shares of the company’s stock, valued at $11,340,725.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 98,000 shares of company stock worth $375,725 in the last three months. Insiders own 54.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Nymox Pharmaceutical Corporation (NYMX) Earns Daily Coverage Optimism Rating of 0.08” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.